Suven Pharmaceuticals Limited (NSE: SUVENPHAR)

Market Cap	284.26B
Revenue (ttm)	9.61B
Net Income (ttm)	2.43B
Shares Out	254.56M
EPS (ttm)	9.54
PE Ratio	117.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230,900
Open	1,120.00
Previous Close	1,130.10
Day's Range	1,108.30 - 1,153.30
52-Week Range	585.20 - 1,360.00
Beta	1.39
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 5, 2025

About Suven Pharmaceuticals

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 1,193
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUVENPHAR

Financial Performance

In 2023, Suven Pharmaceuticals's revenue was 10.51 billion, a decrease of -21.56% compared to the previous year's 13.40 billion. Earnings were 3.00 billion, a decrease of -26.99%.